Antidyskinetic effect of magnesium sulfate in MPTP-lesioned monkeys.
The antiparkinsonian action of an NMDA receptor antagonist, magnesium sulfate (50, 100, and 200 mg/kg), alone and in association with levodopa was explored in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned parkinsonian and control rhesus monkeys. At the three doses tested, magnesium sulfate decreased levodopa-induced dyskinesia [cumulative dyskinetic scores after levodopa: 129 +/- 13; after levodopa and magnesium sulfate: 65 +/- 14 (50 mg/kg), P < 0.001; 64 +/- 10 (100 mg/kg), P < 0.001; 66 +/- 21 (200 mg/kg), P < 0.001, compared to levodopa administration alone]. These results show that magnesium sulfate importantly reduces levodopa-induced dyskinesia.
Chassain
C
C
Unité INSERM EMI 9904, Faculté de Médecine et Pharmacie, 28, place Henri-Dunant, 63001, Clermont-Ferrand, France. kchassin@clermont.inra.fr
Eschalier
A
A
Durif
F
F
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use; D001522:Behavior, Animal / Q000187:drug effects; D004195:Disease Models, Animal; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy*; D005260:Female; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D008253:Macaca mulatta; D008278:Magnesium Sulfate / Q000627:therapeutic use*; D009043:Motor Activity / Q000187:drug effects; D020734:Parkinsonian Disorders / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology
D000978:Antiparkinson Agents; D007980:Levodopa; D008278:Magnesium Sulfate; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine